When:
Time: 8:00am PDT, 11:00am EDT, 4:00pm BST, 5:00pm CEST
Duration: 170 minutes
We invite you to join us at the IQVIA Virtual NLP Summit for an event focused on showcasing value of Natural Language Processing (NLP) for you, our esteemed clients and partners.
With speakers from top pharma and healthcare organizations, a showcase of the latest innovations in AIML and NLP, online networking, and the opportunity to meet with our team on a 1:1 basis, this is an event not to be missed.
The NLP Summit on Tuesday 13th June 2023 at a time suitable for our America audience and will be available for all to watch on-demand. We will be announcing the speaker line up very soon…so watch this space.
The NLP Summit brings together presentations from pharma and healthcare customers who will share their success stories of using NLP to accelerate innovation and impact patient outcomes. Our NLP experts will share exciting product development and technology updates, and how these new technologies can support your business objectives.
The event will include breakout sessions, networking, interactive polls as well as opportunities to speak 1:1 with an NLP expert.
This exciting event attracts speakers and attendees from top pharma, leading government organizations and healthcare organizations. Past speakers include: Sanofi, Chiesi, CSL Behring, Guardant Health, Kaiser Permanente and US FDA.
Check out our eBook from last year’s event.
Who is it for?
VPs, Directors, managers, researchers, analysts, data scientists, informatician and clinicians working in pharma/biotech, healthcare providers and payer organizations looking to learn how to get more value from NLP and learn about the latest innovations.
Why attend?
- Learn how our clients are accelerating innovation and impacting patients with NLP and ML
- Learn about the latest AIML and NLP technologies
- Network with peers, discuss your challenges in breakout sessions
- Our experts are ready to listen – secure a 1:1 session to discuss projects, provide product feedback, request features, or learn more about our new innovations.
Breaking Barriers in Healthcare: Harnessing NLP for Risk Adjustment, Social Determinants of Health, and Precision Medicine - Calum Yacoubian (IQVIA)
NLP has long been adopted in healthcare but never has there been as much interest in its use and potential as there is now. This talk aims to explore the impact that NLP can have in three areas of healthcare: precision medicine, social determinants of health, and risk adjustment.
Precision medicine relies upon complete and accurate capture of whole person data, much of which is in unstructured form. This talk will cover how NLP can unlock treatment impactinginsights from complex clinical data such as pathology reports in oncology patients.
We will also cover the use of NLP to uncover potential health inequities by surfacing patient level social determinants of health such as food insecurity of housing insecurity from clinical notes.
Finally, we will cover how NLP can be used to support in risk stratification of patients – focusing on the use of NLP in Risk Adjustment.
In these examples, we will demonstrate how incorporating human review (Human in the Loop) alongside AI/NLP can lead to highly impactful and explainable results
Addressing Health Equity with Analytics and NLP - Chad Konchak (NorthShore-Edwards-Elmhurst Health)
According to a recent Gartner survey, 96% of respondents say they either have AI in their deployment pipeline or have already initiated projects. At NorthShore University Health System they’re leveraging analytics capabilities and a new AI initiative around natural language processing to aid in health equity; with the mission of reducing healthcare disparities in the care they provide. This work comes under a broader system initiative to prioritize health equity in their measurement systems and ensure that their improvement efforts are conducted through a lens of equity.
Reducing the Noise: Innovative NLP in Healthcare - Paul Milligan (IQVIA)
Across drug discovery and development, scientists, clinicians, product teams and more need access to the information buried in unstructured text. AI technologies can reduce manual effort and provide effective access to the critical information for your decision support.
In this webinar, we will provide an update of some of the latest innovations in AI. We will talk about the ability to bring machine learning models (such as BERT and GPT) into our technology platform, to allow for the combination of multiple NLP technologies. We will demonstrate IQVIA Human Assisted Review Tool, which enables effective document curation to speed up review and generate annotations for learning NLP. We will also showcase some recent use cases from customers, such as Genentech and AstraZeneca.
Use of NLP in Evidence Synthesis - Jenny Uyei & Yuting Kuang (IQVIA)
Over the last two decades, the number of studies conducted and published in healthcare has grown exponentially. In oncology, for example, 1.5 million citations were indexed in PubMed in the 20thcentury (1900 to 1999), and in a relatively short period of time after (2000 to 2023) 3.3 million were added. An explosion of scientific publications was also seen with COVID-19, where in just the last 3 years 362 thousand articles were indexed in PubMed. The sheer volume of studies that is generated each year challenges our ability to identify, summarize, and synthesize scientific knowledge, particularly using traditional manual methods for systematic literature reviews. New technologies, such as natural language processing (NLP) in combination with machine learning, are promising solutions to aid with evidence synthesis projects. The presentation will focus on: 1) current challenges in evidence synthesis, 2) a case study on the use of NLP-based queries to support the identification and extraction of relevant real world data on COVID-19 vaccine effectiveness, antiviral effectiveness, and long COVID, and 3) a case study on the use of NLP to conduct rapid literature reviews.
Staying ahead of the curve: How AI & NLP drive richer insights for medical affairs - Hywel Evans (IQVIA)
NLP & AI approaches can help medical affairs teams better understand the stakeholder, patient and competitive landscapes for a therapy area. The data and insights generated can inform evidence generation, communication strategies, drug development, launch strategies and more.
Field medical interactions are often captured as “MSL Insights” but turning these rich data into insights is often time consuming and manual. NLP can help automate the classification of these notes against key topics such as diagnosis, dosage, comorbidity and others. Similar approaches can be applied to other data sources such as medical information requests and digital interactions, allowing medical affairs teams to be more efficient and responsive to the needs of stakeholders
Join us to learn approaches and examples of how to apply NLP, machine learning, and large language models such as GPT to MSL notes, literature reviews, social media, congress abstracts and more.
Speakers
Chad Konchak
Assistant Vice President, Data Analytics at NorthShore-Edward-Elmhurst HealthChad Konchak
Chad Konchak is the Assistant Vice President of Data Analytics at NorthShore-Edward-Elmhurst Health: a 9-hospital integrated healthcare delivery system in the northern Chicagoland area. In his role, Chad oversees the team responsible for the system’s clinical and operational reporting, analysis and predictive modeling, which focus on leveraging and delivering data that improve the quality of care, patient and physician experience, and efficiency of the healthcare system. Chad is also a faculty of the American College of Healthcare Executives where he teaches a course on healthcare analytics for executives.
Ananth Peddinti
Senior NLP Engineer at City of HopeAnanth Peddinti
Jenny Uyei
Principal, US Health Economics and Outcomes Research, Evidence Synthesis at IQVIAJenny Uyei
Dr. Uyei is a Principal in the Evidence Synthesis practice within IQVIA’s Heath Economics and Outcomes Research. She has more than 18 years of research experience, much of which has been in designing and implementing evidence synthesis projects for a variety of therapeutic areas, including oncology (lung, liver, anal, breast, and biomarker specific), autoimmune and inflammatory diseases (rheumatoid arthritis, ulcerative colitis), infectious diseases (COVID-19, hepatitis C, HIV, anti-microbial resistance), non-communicable diseases (cardiovascular, diabetes, high cholesterol), ophthalmology (wet age-related macular degeneration), psychiatric disorders (bipolar depression, schizophrenia), neurodegenerative disorders (Parkinson’s Disease), rare conditions (arginase-1 deficiency, eosinophilic granulomatosis with polyangiitis), and diagnostic test (PCR, next generation sequencing). In her current and prior work, she utilizes SLR and statistical methods, to synthesize published evidence to support regulatory submissions, evidence generation planning, and strategic decision making, as well as develop manuscripts and conference abstracts.
Prior to joining IQVIA, Dr. Uyei held a Research Scientist and Adjunct Faculty position in the Division of Comparative Effectiveness and Decision Science at New York University. Her research at NYU focused on developing mathematical disease progression models for hepatitis C, liver disease/HCC, and opioid overdose; implementing Bayesian value of information analysis for NIH research prioritization; designing and implementing an observational study on the impact of integrated service delivery in Cape Town, South Africa; and conducting numerous systematic literature reviews for a variety of topics including one for the United Nations on the relationship between gender and HIV. She has also taught courses in decision science, global public health, and epidemiology.
Dr. Uyei’s publications have appeared in The Lancet, The American Journal of Public Health, Health Policy, Health Policy and Planning, the International Journal of Technology Assessment in Health Care, among other clinical peer-reviewed journals. She completed her postdoctoral training in comparative effectiveness research and received her PhD in public health from New York University and received her MPH from the University of California, Los Angeles.
Yuting Kuang
Associate Principal, US Health Economics and Outcomes Research, Evidence Synthesis at IQVIAYuting Kuang
Dr. Kuang is an Associate Principal in the Evidence Synthesis practice within IQVIA’s Heath Economics and Outcomes Research. She has more than 10 years of research experience and provides methodological expertise throughout evidence synthesis research projects. In her past and current work, Dr. Kuang conducts systematic/targeted literature reviews (SLR/TLR), meta-analysis, and network meta-analysis (NMA) to synthesize published evidence and derive insights for pharmaceutical clients, to support regulatory submission, inform strategy planning and product differentiation, and develop publications for research findings.
Dr. Kuang has covered a variety of therapeutic areas in her research projects, including oncology (lung, breast, liver), autoimmune diseases (rheumatoid arthritis, multiple sclerosis), cardiovascular and metabolic diseases (hypercholesterolemia, diabetes), respiratory diseases (asthma), psychiatric disorders (schizophrenia), and vaccine for infectious diseases. Prior to joining IQVIA, Dr. Kuang was a methodologist with Doctor Evidence in Santa Monica, CA, where she designed and implemented evidence synthesis projects for life sciences clients across therapeutic areas.
Dr. Kuang received her PhD in pharmaceutical sciences from the University of Southern California, with strong research background in drug discovery and development of anti-cancer treatment, and profound understanding of molecular pathways and biomarkers. Her work has been published at peer-reviewed journals such as Lung Cancer, Rheumatology and Therapy, Diabetes Therapy, Cancer Research, and Molecular Oncology, and presented at numerous conferences.
Calum Yacoubian
Director NLP Healthcare StrategyCalum Yacoubian
Dr. Calum Yacoubian is Director of Healthcare Product & Strategy at Linguamatics, IQVIA. He is a medical doctor who trained and practiced in the UK before moving into medical technology. He has worked with Natural Language Processing in clinical data for over 5 years and is passionate about the potential for data to drive improved patient outcomes.
Jane Reed
Director, NLP, Safety & RegulatoryJane Reed
Jane Reed is Director of NLP at Linguamatics, an IQVIA company. She is responsible for leading the strategic vision for Linguamatics product portfolio and business development for the pharma and biotech market, with a focus on safety and regulatory. Jane has 20+ years’ experience in vendor companies supplying data products, data integration and analysis, and consultancy to pharma and biotech—with roles at Instem, BioWisdom, Incyte, and Hexagen. Before moving into the life science industry, Jane worked in academia with post-docs in genetics and genomics. Jane holds a MA from Cambridge University and a PhD from Birmingham University.
Constantinos Katevatis
Associate Director, R&D NLPConstantinos Katevatis
Constantinos Katevatis is Associate Director, R&D NLP at Linguamatics, an IQVIA company. He is responsible for developing the strategic vision of Linguamatics’ product portfolio and business development for R&D and clinical operations in the pharma and biotech industries. Constantinos has experience and expertise in NLP-centric data extraction and data management across the pharma product life cycle. Before joining the life science industry, Constantinos completed a doctorate on DNA-based medical devices.
Hywel Evans
Director, NLP for Medical Affairs & CommercializationHywel Evans
Hywel Evans leads the development, application and delivery of IQVIA’s (formerly Linguamatics) NLP offerings within Medical Affairs and Commercial Pharma teams and has been with IQVIA for over 6 years. He also leads the NLP Insight Hub offering, which transforms and integrates information from a wide range of structured and unstructured data sources into a single convenient platform. Hywel was previously a Principal leading Real World Technology & Analytics for the APAC region based in Singapore, leading a team of data scientists and consultants in the design & delivery of analytics solutions, and the development of real-world data assets and collaborations. Hywel has consulting and technology experience across life sciences, healthcare, financial services and consumer industries. He has expertise in building analytics and data teams, delivering data driven strategies, designing and executing behavioral insights and stakeholder engagement initiatives. Prior to joining IQVIA, Hywel was a consultant at Booz&Co and EY. He holds a Master’s degree (MEng) in Engineering from the University of Cambridge.
Paul Milligan
Director, Product StrategyPaul Milligan
Paul started at the company as an Application Specialist in 2005. In his role, he is responsible for product management, marketing, and strategy guidance of I2E, an award-winning agile, high performance enterprise text mining software. Paul also has responsibility for the I2E Web Services API, to allow integration of text mining capabilities into large-scale workflows. He has worked on many customer projects, including analysis of historical pre-clinical records, large-scale extraction of information from patents and semantic annotation for enterprise search. Paul has a PhD from University of Cambridge in computational drug design where his work involved developing algorithms to optimize combinatorial libraries for protein-ligand interactions. Before joining Linguamatics, Paul worked in the Cambridge biotech sector creating bioinformatics and chemoinformatics tools for processing of diverse large databases, including PDB, compound registries and PubMed.
